Remicade Helped By “Slow Start” To Medicare Part B Demo
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson's rheumatoid arthritis therapy Remicade is feeling virtually no impact from a Medicare demonstration project that provides coverage to competing agents, Group Chairman-Biopharmaceuticals Joe Scodari said during the Bear Stearns health care conference in New York Sept. 13